Get Connected:

 

ICER Report Highlights Efficacy and Value of Targeted Therapies for Plaque Psoriasis

In its latest report, the Institute for Clinical and Economic Review (ICER) evaluated the efficacy and value of newer targeted agents that treat moderate-to-severe plaque psoriasis compared with non-targeted therapies.
Published Online: Aug 07,2018
Jennifer Barrett, Associate Editor
In its latest report, the Institute for Clinical and Economic Review (ICER) evaluated the efficacy and value of newer targeted agents that treat moderate-to-severe plaque psoriasis compared with non-targeted therapies.
 
Most notably, treatments guselkumab (Tremfya, Johnson & Johnson) and risankizumab (AbbVie) succeeded in demonstrating greater clinical benefit when compared with non-targeted therapies, according to ICER.
 
At a public meeting, the ICER received input from members of the New England Comparative Effectiveness Public Advisory Council, one of ICER’s 3 independent evidence appraisal committees, based on newly incorporated clinical data and cost information. The updated report, which adds to the 2016 findings, includes recently-approved drugs and risankizumab, which was filed with the FDA for review in April 2018.
 
Council members further voted that evidence was not adequate to show a net health benefit of tildrakizumab (Ilumya, Sun Pharma/Merck) compared with TNFα inhibitors or the TNFα inhibitor certolizumab pegol over the other subcutaneously-administered TNFα inhibitors (adalimumab and etanercept).

Click to continue reading on Specialty Pharmacy Times.